+ T-cells and that of antibodies neutralizing virus epithelial infection (AbNEI) in the control of CMV DNAemia were investigated in 39 CMV-seropositive allogeneic stem-cell transplant (Allo-SCT) recipients with (n524) or without (n515) CMV DNAemia. AbNEI levels were monitored prospectively by means of a neutralization assay employing retinal epithelial cells (ARPE-19) and the recombinant CMV strain BADrUL131-Y4. Quantification of CMV-specific polyfunctional CD8 + T-cells (expressing two or three of the following markers: IFN-cc, TNF-a and CD107a) in whole blood was performed by flow cytometry for intracellular cytokine staining. We found no differences in the dynamic pattern of AbNEI in patients with or without subsequent CMV DNAemia. Baseline and peak AbNEI titres were not predictive of the dynamics of CMV replication within episodes. No correlation was found between CMV DNA loads and AbNEI levels during episodes of CMV DNAemia (r50.09; 95 % confidence interval 20.52 to 0.64; P50.78). The detection of pp65/IE-1 CMV-specific polyfunctional CD8 + T-cells was associated with low-level virus replication within subsequent episodes of CMV DNAemia. Interestingly, the presence of AbNEI titres (inverse) .4.7 log 2 was predictive of the occurrence of CMV DNAemia (sensitivity, 83 %; specificity, 80 %). Our findings provide an insight to the role of humoral and cellular immunity in the control of CMV infection in an Allo-SCT setting.
INTRODUCTION
Protection from and clearance of cytomegalovirus (CMV) viraemia in allogeneic stem-cell transplant (Allo-SCT) recipients is critically dependent upon the reconstitution and adequate expansion, respectively, of functional CMVspecific T-cells (Solano & Navarro, 2010) . Whether CMVspecific antibodies exerting antiviral activities contribute in a relevant way to these purposes has not been elucidated. In this context, the beneficial effect of the administration of CMV-specific human hyperimmunoglobulin on minimizing the incidence and fatal outcome of CMV end-organ disease, claimed in this clinical setting, has never been proven conclusively (Guglielmo et al., 1994) . Furthermore, contradictory data have been published on the role of CMV-specific neutralizing antibodies in the prevention or control of CMV viraemia (Muñoz et al., 2001; Schoppel et al., 1998; Volpi et al., 1999) ; in these studies, neutralizing antibodies were quantified by means of a classical neutralization assay involving the use of the CMV AD169 strain and human-derived fibroblasts, which mostly measures antibody levels against gB and the glycoprotein complex gH-gL, both essential for infection of human fibroblasts (Vanarsdall et al., 2008) . Recently, the virion glycoprotein complex gH-gLpUL131A-pUL130-pUL128 has been shown to be required for infection of endothelial, epithelial and myeloid cells (Gerna et al., 2005; Hahn et al., 2004; Ryckman et al., 2008a, b; Wang & Shenk, 2005a) , all of which are key targets for CMV pathogenesis in the human host. Neutralizing antibodies targeting this pentameric complex are known to display a much higher potency in neutralizing virus infection of epithelial and endothelial cells than those against gB (Macagno et al., 2010) . The AD169 strain of CMV carries a defective UL131 ORF, and thus antibodies against this pentameric complex are not measured in the classical neutralization assay (Hahn et al., 2004) . Antibodies against neutralizing epitopes of the complex gH-gL-pUL131A-pUL130-pUL128 have been shown to correlate with virus control in immunocompetent individuals (Lilleri et al., 2012) and protection from fetal CMV transmission (Lilleri et al., 2013) . Here, we investigated in parallel the role of CMV-specific antibodies that neutralize epithelial cell infection (AbNEIs) and that of CMV-specific polyfunctional CD8
+ T-cells in the control of CMV DNAemia in a cohort of Allo-SCT recipients.
RESULTS

Incidence of CMV DNAemia
A total of 24 out of 39 patients (61.5 %) developed a first episode of CMV DNAemia within the first 100 days after Allo-SCT (median 30 days; range 26-42 days). All episodes were eventually controlled. Twelve episodes required the administration of pre-emptive antiviral therapy. CMV DNAemia was spontaneously cleared in the remaining 12 patients.
Kinetics of CMV-specific AbNEIs in patients with or without CMV DNAemia
We first assessed the kinetics of AbNEIs in patients with or without subsequent CMV DNAemia. Sequential sera (n560) were available from 18 patients subsequently having CMV DNAemia (median, three per patient; range, two to eight per patient). Serial sera (n576) from 15 patients with no CMV DNAemia (median, five per patient; range, three to eight per patient) obtained within a comparable time frame were also available for analysis and served as controls. The kinetic profiles of AbNEIs did not differ notably between patients in the study groups (Fig.  1a, b) . CMV-specific AbNEI levels were found to remain stable in 13/18 and 10/15 patients with or without subsequent CMV DNAemia, respectively (P50.73). Increasing, decreasing or fluctuating levels of AbNEI levels were observed at comparable frequencies among individuals belonging to both groups (Pi0.5). Data on CMV (AD169)-specific IgG levels, as measured by chemiluminescent assay (CLIA), were available from 31 patients (median, three samples per patient; range, one to six samples). All sera having detectable AbNEIs were also reactive by the CMV IgG CLIA. As shown in Fig. 1(c, d) , the kinetics CMV-specific neutralizing antibodies and CMV DNAemia pattern of CMV IgG antibodies was found to be comparable in patients with or without subsequent CMV DNAemia, with a rather similar number of patients displaying stable, increasing or decreasing antibody levels in both study groups.
Quantification of CMV-specific AbNEIs allows anticipation of the occurrence of CMV DNAemia
We next investigated whether AbNEI levels measured either at the time of or early after Allo-SCT were indicative of the risk of CMV DNAemia. The data for each patient of the cohort are shown in Table 1 . We found that both baseline (median, day 0; range, day 21 to 16) and peak (median, day 14; range, days 0-32) AbNEI levels were significantly higher in patients who went on to develop CMV DNAemia than in those who did not (Fig. 2a, b , respectively). Receiver operating characteristics (ROC) curve analyses indicated that a cut-off titre of 4.7 log 2 (1/120) for both baseline and peak AbNEIs discriminated fairly well (sensitivity, 83 %; specificity, 80 %) between patients with or without subsequent CMV DNAemia (Fig. 3) . In fact, the odds ratio for developing CMV DNAemia was 20.0 [95 % confidence interval (CI) 3.81-105.11] for patients with AbNEI titres above the referred threshold. In contrast, both baseline and peak CMV-specific IgG titres were comparable in both study groups (Fig. 2c, d ). Thus, a CMV IgG threshold level discriminating between patients with or without subsequent CMV DNAemia could not be established. Of note was the fact that patients displaying baseline and peak AbNEI titres either above or below this cut-off were comparable in terms of pre-transplant and post-transplant clinical factors known to modulate the risk of CMV DNAemia (data not shown).
The dynamics of CMV DNAemia is not influenced by CMV-specific AbNEIs
We then investigated whether AbNEI levels measured prior to the occurrence of CMV DNAemia allowed the inference of the dynamics of virus replication within episodes. As shown in Table 2 , neither initial nor peak plasma CMV DNA loads differed significantly between patients displaying baseline or peak AbNEI levels above or below a titre of 4.7 log 2 . Likewise, the need for pre-emptive antiviral therapy and the duration of episodes of CMV DNAemia were not associated with AbNEI levels. Furthermore, no significant correlation was observed between peak AbNEI levels and peak plasma CMV DNA loads (r520.27; 95 % CI 20.74 to 0.38; P50.40).
We next investigated the kinetics of AbNEI levels relative to that of CMV DNA load during episodes of CMV DNAemia. A total of 110 sera (median, 7.5; range, 2-24) from 20 patients with CMV DNAemia were available for analysis. No correlation was found between AbNEI levels and plasma CMV DNA loads (r50.09; 95 % CI 20.52 to 0.64; P50.78). In fact, AbNEI levels remained constant in 14/22 episodes in the face of decreasing CMV DNAemia levels. In the remaining eight episodes, decreasing (n54), fluctuating (n53) or increasing levels of AbNEI levels were seen. The dynamics of AbNEI levels in patients without CMV DNAemia were similar (stable levels in 11/13 patients). Likewise, CMV IgG levels were not correlated with CMV DNA load within episodes of active CMV infection (r50.19; 95 % CI 20.28 to 0.74; P50.68).
CMV-specific polyfunctional CD8 1 T-cells modulate the rate of CMV replication within episodes of active CMV infection T-cell immunity data were available from 29 out of the 39 patients included in the cohort, of whom 19 had CMV DNAemia within the study period. Seven out of these 19 patients developed CMV DNAemia prior to the first immunological monitoring time point and were excluded from the analyses reported below. The data for each patient are shown in Table 1 , and representative flow cytometry plots of these patients are depicted in Fig. 4 . The prevalence of detectable polyfunctional CD8 + T-cell responses (any combination of bifunctional T-cells and/or trifunctional T-cells) was found to be comparable in patients with or without subsequent CMV DNAemia (8/12 in patients with CMV DNAemia and 6/10 in patients without CMV DNAemia; P50.87). CMV-specific polyfunctional CD8 + T-cell levels did not differ significantly between patients with or without subsequent CMV DNAemia (median, 0.31 cells ml
21
; range, 0.02-2.60 cells ml 21 ; and median, 0.62 cell ml 21 ; range, 0.02-2.01 cells ml
, respectively; P50.91). Nevertheless, as shown in Table 3 , patients displaying detectable polyfunctional CD8 + T-cell responses at day 30 after Allo-SCT had lower initial and peak CMV DNA loads in subsequent episodes of CMV DNAemia than those who did not, although a statistical significance was not reached. Furthermore, episodes of CMV DNAemia in the latter patients lasted significantly longer than those in the former patients.
DISCUSSION
To the best of our knowledge, this is the first study assessing the potential role of CMV-specific AbNEIs in the control of CMV infection in an Allo-SCT setting. Prior studies measuring CMV-specific antibodies neutralizing fibroblast infection failed to provide convincing evidence of a role for these antibodies in either the prevention or clearance of CMV viraemia (Muñoz et al., 2001; Schoppel et al., 1998; Volpi et al., 1999) . Here, we performed a neutralization assay in which neutralizing antibodies probably target epitopes within one or more of the components of the glycoprotein complex gH-gL-pUL131A-pUL130-pUL128 or even epitopes on gB that are specifically involved in pHdependent triggering and/or with interactions between gB and the pentameric glycoprotein complex. Our data suggested that CMV-specific AbNEIs are unlikely to play a major role in either the prevention or resolution of CMV DNAemia. First, the dynamic pattern of AbNEI levels in patients who later developed CMV DNAemia was indistinguishable from that seen in patients who did not. Second, the kinetics and the level of CMV replication within episodes of CMV DNAemia were independent of AbNEI levels measured prior to the occurrence of CMV DNAemia. Third, no apparent relationship between CMV DNA load kinetics and AbNEI level dynamics was observed within episodes of CMV DNAemia. In fact, stable AbNEI levels were frequently seen concomitant with decreasing CMV DNA load levels. Strikingly, patients exhibiting high baseline and peak AbNEI levels were more likely to develop CMV DNAemia. In fact, a cut-off AbNEI level was established (titre of 4.7 log 2 ) that discriminated fairly well (specificity and sensitivity i80 %) between patients with or without subsequent CMV DNAemia. In contrast, the levels of CMV (AD169)-specific IgGs measured by CLIA were not predictive of the occurrence of CMV DNAemia. In our opinion, if AbNEIs displayed a relevant role in conferring protection against CMV viraemia, the opposite phenomenon would be expected to occur, as has been shown for CMV-specific functional T-cells Tormo et al., 2010a Tormo et al., , b, 2011 . Several non-mutually exclusive explanations may account for this finding. First, CMV reactivation at tissue or mucosal sites occurring either during conditioning or very early after transplant may have boosted residual memory B-cells in the recipient or memory B-cells transferred within the allograft (Yamazaki et al., 2014) to produce antibodies with such functional properties. Second, baseline serum levels of AbNEIs may reflect latent viral load, which ultimately determines the overall risk of CMV reactivation (Forster et al., 2010; Reddehase et al., 1994) . Third, the possibility exists that a fraction of the antibodies quantified in the neutralization assay employed in the current study may enhance CMV infectivity in this clinical setting. In this sense, CMV-specific antibodies of low neutralizing activity have been shown to enhance human placental infection by allowing receptor-mediated transcytosis of CMV-IgG complexes that retain infectivity by Fc receptors (Maidji et al., 2006) .
New compounds exhibiting higher intrinsic activity against CMV and a better safety profile than (val)ganciclovir have been developed (Boeckh et al., 2015) . This has renewed interest in antiviral prophylaxis for the prevention of CMV-related morbidity in Allo-SCT recipients (Chemaly et al., 2014) . The identification of biomarkers predicting the occurrence of CMV viraemia (particularly those episodes requiring the administration of pre-emptive antiviral therapy) would allow the inception of antiviral prophylaxis on an individual basis according to the patient's risk (targeted prophylaxis). In this context, quantification of AbNEIs may serve this purpose.
There is increasing evidence to show that polyfunctional Tcells are superior to those exhibiting monofunctional properties in controlling acute and chronic viral infections, such as + Tcell immunity were available from a number of patients who either did or did not develop a subsequent episode of CMV DNAemia. In our clinical setting, the occurrence of CMV DNAemia could not be reliably predicted on the basis of either the presence or absence of detectable polyfunctional CD8 + T-cell responses or the total number of CMV-specific polyfunctional CD8
+ T-cells. Nevertheless, the mere presence of these functional T-cell types was associated with lower levels of CMV replication within episodes of active CMV infection, and hence with a shorter duration of episodes. This is in line with previously published data (Lilleri et al., 2008; Muñoz-Cobo et al., 2012; Zhou et al., 2009) , and further highlights the crucial role of adaptive T-cell immunity in the control of CMV viraemia in Allo-SCT recipients.
The apparent lack of contribution of CMV-specific AbNEIs to the control of CMV infection in the CMV-seropositive Allo-SCT setting reported here is in contrast to that seen in the context of primary CMV infection during pregnancy (Lilleri et al., 2012 (Lilleri et al., , 2013 . In this latter setting, fetal CMV transmission was found to correlate with delayed generation of maternal antibodies to the gH-gL-pUL131A-pUL130-pUL128 complex during primary infection. Taken together, these data point to a more efficient role of AbNEIs in the control of CMV replication in the immunocompetent CMVnaïve host than in that occurring in chronically infected immunosuppressed individuals as a result of virus reactivation or reinfection. Further studies are needed to shed light on this issue.
It is increasingly being appreciated that immune mechanisms exerting control over CMV infection are possibly redundant (Solano & Navarro, 2010) . In this sense, data obtained in the murine cytomegalovirus model have indicated that adoptive transfer of memory B-cells from immune animals protected T-cell-and B-cell-deficient RAG-1 2/2 mice from lethal challenge. This strategy was also effective in protecting from an already ongoing viral infection (Klenovsek et al., 2007) . In this context, it is of note that almost 50 % of patients in our cohort exhibited detectable CMV-specific polyfunctional CD8 + T-cell responses. Hence, our conclusions must be taken in the context of our particular group of patients and should not be extrapolated to patients displaying distinct immunological backgrounds.
In summary, our data argue against a major role of CMVspecific AbNEIs in the control of CMV infection in an Allo-SCT setting, whilst reinforcing the relevance of T-cell . ROC curve analysis for CMV-specific AbNEIs (ROC curves for baseline and peak antibody titres were similar) indicating the optimal cut-off value (titre of 4.7 log 2 ) for discriminating between patients with or without subsequent CMV DNAemia (sensitivity, 83 %; specificity, 80 %). Dots represent different log 2 antibody titres. immunity for that purpose. Further studies involving larger cohorts are nevertheless needed to either confirm or refute our observations.
METHODS
Patients. The current cohort consisted of 39 non-consecutive CMVseropositive Allo-SCT recipients (20 males and 19 females) undergoing Allo-SCT (peripheral blood, n534; umbilical cord blood, n54; bone marrow, n51) for haematological malignancy at the Hospital Clínico Universitario of Valencia between 2010 and 2013. The median age of patients was 52 years (range, 25-66 years). Donors were HLA matched (71.8 %) or HLA mismatched (28.9 %). The conditioning regimen was non-myeloablative in 71.8 % of transplants. Donors were CMV seropositive in 23 cases and CMV seronegative in the remaining 16 cases. No patients received intravenous immunoglobulins during the study. The study period comprised the first 100 days following transplantation. Only initial episodes of CMV DNAemia were considered for the analyses reported here. The study was approved by the local Review Board and Ethics Committee. All patients gave written informed consent prior to participation in the study.
Management of CMV infection. Monitoring of plasma CMV DNAemia was performed once a week using a real-time PCR assay (CMV real-time PCR or Abbott RealTime CMV; Abbott Molecular) (Clari et al., 2013; Giménez et al., 2014; Gimeno et al., 2008) . Patients were treated pre-emptively with antivirals as described previously Tormo et al., 2010a Tormo et al., , b, 2011 . CMV DNAemia (active CMV infection) was defined as the detection of any level of CMV DNA in plasma. The duration of a given episode of CMV DNAemia was that between the day of the first positive PCR result and the day of the first negative (undetectable) result.
Cells and virus. Human ARPE-19 retinal pigment epithelial cells (ATCC CRL-2302) were cultured in high-glucose Dulbecco's modified Eagle's medium (DMEM; Gibco-BRL) supplemented with 10 % FCS (HyClone Laboratories), 10 000 IU penicillin l 21 (Gibco-BRL), 10 mg streptomycin (Gibco-BRL) l 21 . CMV strain BADrUL131-Y4 was kindly provided by Dr T. Shenk (Princeton University, USA). This strain is derived from a bacterial artificial chromosome clone of the CMV strain AD169 genome that was modified in Escherichia coli to express a functional UL131 protein, which permits replication in either ARPE-19 or MRC-5 cells (Hahn et al., 2003; Wang & Shenk, 2005b) . Viral titres of CMV BADrUL131-Y4 were determined by limiting dilution in 96-well plates using MRC-5 cells.
Neutralization assay. A neutralization assay was performed following a previously published protocol with some modifications (Cui et al., 2008) . Heat-inactivated sera were serially diluted (twofold) in DMEM (from 1 : 5 to 1 : 2560). Fifty microlitres of the respective serum dilution was incubated in triplicate (for 2 h at 37 uC) with the BADrUL131-Y4 virus inoculum (m.o.i. of 0.5 in 50 ml DMEM). Virus-antibody mixtures were then added to confluent ARPE-19 monolayers previously seeded in 96-well microtitre plates (clear/flatbottomed 96-well plates; Costar). Infected and mock-infected cells were used as positive and negative controls, respectively. After 48 h of incubation at 37 uC in a 5 % CO 2 atmosphere, the cells were washed and fixed with cold PBS : acetone solution diluted 1 : 4. Cells were stained with a p72 [immediate-early protein 1 (IE-1)]-specific mAb (clone 8B1.2; Millipore) diluted 1 : 2000 and washed with PBS+0.05 % Tween 20. An HRP-conjugated IgG anti-mouse secondary antibody (Sigma-Aldrich) diluted 1 : 1000 was added. One hundred microlitres of peroxidase substrate (3,39,5,59-Tetramethylbenzidine Liquid Substrate, Supersensitive, for ELISA; Sigma-Aldrich) was added to the mixture and incubated for 15 min. The reaction was stopped with 50 ml of 0.5 M sulfuric acid and the absorbance was measured in a microplate reader with a 450-490 nm filter. The mean (triplicate) serum dilution inhibiting virus infectivity by 50 % or more with respect to infected cell controls was reported as the neutralizing antibody titre. Sera were scheduled to be obtained on a weekly basis. Variations in antibody titres of w1 log 2 were deemed to be significant. A total of 338 sera were subjected to analysis.
CMV antibody assay. CMV (AD169)-specific IgG antibodies were measured by a CLIA (Chemiluminescent Architect CMV IgG assay; Abbott) following the recommendations of the manufacturer. IgG antibody levels w6 absorbance units ml 21 were considered reactive. Variations in CMV IgG levels w20 % (the interassay coefficient of variation, as reported by the manufacturer, +2 SD) were considered to be significant.
Enumeration of polyfunctional CMV-specific CD8
1 T-cells.
Quantification of pp65 and IE-1-specific monofunctional (IFN-c, TNF-a and CD107a), bifunctional (IFN-cc/TNF-a, IFN-c/CD107a and TNF-a/CD107a) and trifunctional (IFN-c/TNF-a/CD107a) CMV-specific CD8 + T-cells was performed by flow cytometry for intracellular cytokine staining at day +30 after transplant, as described previously (Muñoz-Cobo et al., 2012) . Briefly, whole blood samples (0.5 ml) were simultaneously stimulated with two sets of 15mer overlapping peptides encompassing the sequence of pp65 and IE-1 CMV proteins (1 mg ml 21 per peptide), obtained from JPT peptide Technologies (Berlin, Germany), in the presence of 1 mg ml 21 of co-stimulatory mAbs to CD28 and CD49d, an anti-CD107a mAb coupled to allophycocyanin (APC), brefeldin (5 mg ml
21
) and monensin (1 mM) for 6 h at 37 uC. The specimens were maintained at room temperature until stimulation, which was performed within 24 h after sampling. The cells were washed in PBS+2 % FCS, lysed in BD FACS lysis solution, stained with surface markers (anti-CD8-PerCP-Cy5-5 and anti-CD3-APC-Cy7), permeabilized (BD FACS Permeabilizing Solution 2), washed and finally stained for intracellular cytokines (anti-IFN-c-FITC and anti-TNF-a-phycoerythrin). All antibodies and solutions were purchased from Becton Dickinson. The cells were stored at 4 uC in PBS+1 % formaldehyde, acquired within 4 h in a BD FACScantoII flow cytometer (BD Biosciences Immunocytometry Systems) and analysed with the program BD FACS Diva Software (BD Biosciences). Negative controls (absence of peptide stimulation) were processed in parallel for all experiments. After initial gating on lymphocytes, cells were selected Table 1 ) are shown. Blood specimens of these patients were stimulated, stained and acquired on different days. Cells were gated on forward/side-scatter characteristics to identify viable lymphocytes (not shown), followed by gating on CD3 + and CD8 + staining, and then further gated based on the expression of IFN-c, TNF-a and CD107a (see Fig. 4 ). Boolean gating analysis was performed to enumerate the frequencies of all possible combinations. The total number of each CD8 + T-cell subpopulation was calculated by multiplying the corresponding percentage of CMV-specific T-cells (after background subtraction) by the absolute number of CD8 + T-cells. Specific (detectable) responses were considered as those that were w0.1 % (mean+2 SD of CMV-seronegative controls) for IFN-c-, TNF-a-and CD107a-expressing CD8 + T-cell populations. Polyfunctional CD8 + T-cells were those that were positive for two (bifunctional) or three (trifunctional) markers.
Statistical analysis. Data were analysed with the aid of the statistical package SPSS version 20.0 (SPSS). Differences between medians were compared using the Mann-Whitney U test. Spearman's rank test was used to analyse correlations between continuous variables. Two-sided exact P values are reported. Pv0.05 was considered statistically significant. ROC curve analysis was also performed with the SPSS program. (bifunctional) or three (trifunctional) of the following markers: IFN-c/TNF-a, IFN-c/CD107a] at day +30 after transplant as determined by flow cytometry for intracellular cytokine staining. Detectable responses were considered as those that were .0.1 % (mean+2 SD of CMV-seronegative controls) after background subtraction for IFN-c-, TNF-a-and CD107a-expressing CD8 + T-cell populations. DDifferences between medians were compared using the Mann-Whitney U test. Two-sided exact P values are reported. P,0.05 was considered statistically significant.
